OTCMKTS:MRMD MariMed (MRMD) Stock Forecast, Price & News $0.41 -0.01 (-1.22%) (As of 05:34 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4450-Day Range$0.37▼$0.5252-Week Range$0.28▼$0.77Volume157,169 shsAverage Volume256,968 shsMarket Capitalization$140.99 millionP/E Ratio20.26Dividend YieldN/APrice Target$0.85 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest MariMed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.3% Upside$0.85 Price TargetShort InterestHealthy0.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMariMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.85, MariMed has a forecasted upside of 107.3% from its current price of $0.41.Amount of Analyst CoverageMariMed has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.01% of the outstanding shares of MariMed have been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMariMed does not currently pay a dividend.Dividend GrowthMariMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRMD. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for MRMD on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MariMed insiders have not sold or bought any company stock.Percentage Held by Insiders23.34% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.27% of the stock of MariMed is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of MariMed is 20.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.58.Price to Earnings Ratio vs. SectorThe P/E ratio of MariMed is 20.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.05.Price to Book Value per Share RatioMariMed has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MariMed (OTCMKTS:MRMD) StockMariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.Read More Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Stock News HeadlinesMay 22, 2023 | fool.comMariMed (OTC: MRMD)May 10, 2023 | finanznachrichten.deMariMed Inc.: MariMed Reports First Quarter 2023 EarningsMay 31, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 10, 2023 | msn.comMariMed Reports Earnings: Q1 Revenue Falls 4% Sequentially, CEO Pleased With 'Solid Quarter'May 8, 2023 | finance.yahoo.comMariMed Reports First Quarter 2023 EarningsApril 29, 2023 | americanbankingnews.comContrasting MariMed (OTCMKTS:MRMD) and Mannatech (NASDAQ:MTEX)April 27, 2023 | americanbankingnews.comMariMed (OTCMKTS:MRMD) & Jushi (OTCMKTS:JUSHF) Head to Head SurveyApril 25, 2023 | finance.yahoo.comMariMed Announces Opening of Panacea Wellness Dispensary in Beverly, MassachusettsMay 31, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 19, 2023 | americanbankingnews.comMariMed Inc. (OTCMKTS:MRMD) Short Interest UpdateApril 17, 2023 | finance.yahoo.comMariMed Expands Board With the Addition of Kathleen TuckerApril 11, 2023 | finance.yahoo.comMariMed Announces First Quarter 2023 Earnings DateApril 4, 2023 | finance.yahoo.comMariMed Receives Approval to Once Again Produce and Sell High-Dosage Edibles in MarylandApril 3, 2023 | finance.yahoo.comMariMed to Participate in Upcoming Investor ConferencesApril 2, 2023 | americanbankingnews.comMariMed (OTCMKTS:MRMD) and Tauriga Sciences (OTCMKTS:TAUG) Head to Head ComparisonMarch 25, 2023 | benzinga.comMariMed Stock (OTC:MRMD), DividendsMarch 6, 2023 | finance.yahoo.comMariMed Inc. (PNK:MRMD) Q4 2022 Earnings Call TranscriptMarch 5, 2023 | finanznachrichten.deMariMed Inc.: MariMed Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 5, 2023 | msn.comLatest Executive Changes In Marijuana Industry, New Appointments & MoreMarch 1, 2023 | finance.yahoo.comMariMed Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 1, 2023 | finance.yahoo.comMariMed Board of Directors Appoints Edward Gildea as Chairman and Jon Levine as Chief Executive OfficerFebruary 21, 2023 | finance.yahoo.comMariMed To Expand Footprint in Massachusetts With Dispensary Acquisition in QuincyFebruary 1, 2023 | finance.yahoo.comMariMed Announces Fourth Quarter 2022 Earnings DateJanuary 24, 2023 | finance.yahoo.comMariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth PlansJanuary 17, 2023 | finance.yahoo.comMariMed Strengthens Sales, Marketing, and R&D Teams With Senior Executive HiresDecember 30, 2022 | insidermonkey.comMariMed Inc. (OTC:MRMD) Q3 2022 Earnings Call TranscriptDecember 21, 2022 | finance.yahoo.comMariMed Adds Candy Cane Flavored Vape Pen To Its InHouse Brand Line-up for the Holiday SeasonSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Company Calendar Last Earnings11/15/2021Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MRMD CUSIPN/A CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.85 High Stock Price Forecast$0.85 Low Stock Price Forecast$0.85 Forecasted Upside/Downside+107.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.02 Trailing P/E Ratio20.51 Forward P/E RatioN/A P/E GrowthN/ANet Income$13.47 million Net Margins6.30% Pretax Margin9.80% Return on Equity17.80% Return on Assets6.40% Debt Debt-to-Equity Ratio0.73 Current Ratio2.42 Quick Ratio1.50 Sales & Book Value Annual Sales$134.01 million Price / Sales1.07 Cash Flow$0.06 per share Price / Cash Flow6.81 Book Value$0.19 per share Price / Book2.16Miscellaneous Outstanding Shares348,130,000Free Float266,874,000Market Cap$142.73 million OptionableNot Optionable Beta3.02 Key ExecutivesJon R. LevinePresident, CEO, Secretary, Treasurer & DirectorTimothy ShawChief Operating OfficerSusan M. VillareChief Financial OfficerJay O’MalleyVice President-Marketing & Research & DevelopmentRyan CrandallChief Revenue OfficerKey CompetitorsMind Medicine (MindMed)NASDAQ:MNMDBright GreenNASDAQ:BGXXAscend WellnessOTC:AAWHChromaDexNASDAQ:CDXCAurora CannabisNYSE:ACBView All Competitors MRMD Stock - Frequently Asked Questions Should I buy or sell MariMed stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares. View MRMD analyst ratings or view top-rated stocks. What is MariMed's stock price forecast for 2023? 1 brokerages have issued 1-year price targets for MariMed's shares. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they anticipate the company's stock price to reach $0.85 in the next twelve months. This suggests a possible upside of 107.3% from the stock's current price. View analysts price targets for MRMD or view top-rated stocks among Wall Street analysts. How have MRMD shares performed in 2023? MariMed's stock was trading at $0.3562 on January 1st, 2023. Since then, MRMD shares have increased by 15.1% and is now trading at $0.41. View the best growth stocks for 2023 here. Are investors shorting MariMed? MariMed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 16,000 shares, an increase of 100.0% from the April 15th total of 8,000 shares. Based on an average daily volume of 512,100 shares, the days-to-cover ratio is presently 0.0 days. View MariMed's Short Interest. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) announced its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $33.21 million for the quarter. MariMed had a trailing twelve-month return on equity of 17.80% and a net margin of 6.30%. What guidance has MariMed issued on next quarter's earnings? MariMed updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00M-, compared to the consensus revenue estimate of $149.65 million. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA). What is MariMed's stock symbol? MariMed trades on the OTCMKTS under the ticker symbol "MRMD." How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MariMed's stock price today? One share of MRMD stock can currently be purchased for approximately $0.41. How much money does MariMed make? MariMed (OTCMKTS:MRMD) has a market capitalization of $142.73 million and generates $134.01 million in revenue each year. The company earns $13.47 million in net income (profit) each year or $0.02 on an earnings per share basis. How many employees does MariMed have? The company employs 260 workers across the globe. How can I contact MariMed? MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com. This page (OTCMKTS:MRMD) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.